Revive Therapeutics Ltd. (RVVTF)
OTCMKTS · Delayed Price · Currency is USD
0.0136
+0.0003 (2.26%)
Aug 1, 2025, 3:14 PM EDT

Revive Therapeutics Company Description

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders.

It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.

The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases.

Revive Therapeutics Ltd. is based in Toronto, Canada.

Revive Therapeutics Ltd.
Revive Therapeutics logo
CountryCanada
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees2
CEOMichael Frank

Contact Details

Address:
The Canadian Venture Building
Toronto, Ontario M5C 1P1
Canada
Phone888-901-0036
Websiterevivethera.com

Stock Details

Ticker SymbolRVVTF
ExchangeOTCMKTS
Fiscal YearJuly - June
Reporting CurrencyCAD
ISIN NumberCA7615161030
SIC Code2836

Key Executives

NamePosition
Michael FrankChairman and Chief Executive Officer
Carmelo Marrelli ACIS, B.Comm., C.A., C.P.A., CGA, CPAChief Financial Officer
Dr. Kelly T. McKee Jr., M.D., M.P.H.Chief Scientific Officer Consultant
Dr. Onesmo Mpanju Ph.D.Chief Regulatory Affairs Consultant